Literature DB >> 9422361

In vivo electrochemical studies of dopamine clearance in the rat substantia nigra: effects of locally applied uptake inhibitors and unilateral 6-hydroxydopamine lesions.

A F Hoffman1, G A Gerhardt.   

Abstract

High-speed chronoamperometric recordings were used to measure the uptake and clearance of locally applied dopamine (DA) within the substantia nigra (SN) of anesthetized rats. To establish that DA clearance within the SN was mediated primarily by the DA transporter (DAT) rather than the norepinephrine transporter (NET) or the serotonin transporter (SERT), we locally applied uptake inhibitors with different selectivity profiles for the various amine transporters. Nomifensine, a DAT/NET inhibitor, significantly potentiated both the amplitude and the time course of the DA signals. In contrast, neither the selective NET inhibitor desipramine, nor the selective SERT inhibitor citalopram affected the DA signal, suggesting that NET and SERT do not contribute to DA uptake and clearance within the regions of the SN studied over the concentration ranges (1-5 microM) used. In unilaterally 6-hydroxydopamine-lesioned rats, the time course of the DA signal was increased in both the lesioned SN and striatum, relative to the unlesioned hemisphere, indicating loss of DAT and decreased DA uptake and clearance. In addition, when identical amounts of DA were injected in the striatum and SN, peak signal amplitudes were larger in the SN, suggesting that the amplitudes are related to the number of DAT sites in a given region of brain tissue. For signals of equivalent amplitudes, clearance rates were lower in the SN than in the striatum, consistent with a lower capacity for DAT-mediated DA uptake within the SN. These results suggest that the DAT is the major transporter responsible for DA clearance within the rat SN.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9422361     DOI: 10.1046/j.1471-4159.1998.70010179.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  17 in total

1.  Aberrant glutamate signaling in the prefrontal cortex and striatum of the spontaneously hypertensive rat model of attention-deficit/hyperactivity disorder.

Authors:  Erin M Miller; Francois Pomerleau; Peter Huettl; Greg A Gerhardt; Paul E A Glaser
Journal:  Psychopharmacology (Berl)       Date:  2014-02-28       Impact factor: 4.530

2.  Impaired neurotransmission caused by overexpression of α-synuclein in nigral dopamine neurons.

Authors:  Martin Lundblad; Mickael Decressac; Bengt Mattsson; Anders Björklund
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-06       Impact factor: 11.205

Review 3.  Monitoring rapid chemical communication in the brain.

Authors:  Donita L Robinson; Andre Hermans; Andrew T Seipel; R Mark Wightman
Journal:  Chem Rev       Date:  2008-06-25       Impact factor: 60.622

4.  Novel multifunctional pharmacology of lobinaline, the major alkaloid from Lobelia cardinalis.

Authors:  Dustin P Brown; Dennis T Rogers; Francois Pomerleau; Kirin B Siripurapu; Manish Kulshrestha; Greg A Gerhardt; John M Littleton
Journal:  Fitoterapia       Date:  2016-04-20       Impact factor: 2.882

5.  Insulin resistance impairs nigrostriatal dopamine function.

Authors:  J K Morris; G L Bomhoff; B K Gorres; V A Davis; J Kim; P-P Lee; W M Brooks; G A Gerhardt; P C Geiger; J A Stanford
Journal:  Exp Neurol       Date:  2011-06-15       Impact factor: 5.330

6.  Dopamine release from serotonergic nerve fibers is reduced in L-DOPA-induced dyskinesia.

Authors:  Nina Nevalainen; Sara Af Bjerkén; Martin Lundblad; Greg A Gerhardt; Ingrid Strömberg
Journal:  J Neurochem       Date:  2011-05-25       Impact factor: 5.372

7.  Enhanced dopamine transporter activity in middle-aged Gdnf heterozygous mice.

Authors:  Ofelia M Littrell; Francois Pomerleau; Peter Huettl; Stewart Surgener; Jacqueline F McGinty; Lawrence D Middaugh; Ann-Charlotte Granholm; Greg A Gerhardt; Heather A Boger
Journal:  Neurobiol Aging       Date:  2010-12-08       Impact factor: 4.673

8.  Modeling Parkinson's disease pathology by combination of fibril seeds and α-synuclein overexpression in the rat brain.

Authors:  Poonam Thakur; Ludivine S Breger; Martin Lundblad; Oi Wan Wan; Bengt Mattsson; Kelvin C Luk; Virginia M Y Lee; John Q Trojanowski; Anders Björklund
Journal:  Proc Natl Acad Sci U S A       Date:  2017-09-12       Impact factor: 11.205

9.  Altered glutamate release in the dorsal striatum of the MitoPark mouse model of Parkinson's disease.

Authors:  Ariana Q Farrand; Rebecca A Gregory; Cristina M Bäckman; Kristi L Helke; Heather A Boger
Journal:  Brain Res       Date:  2016-09-20       Impact factor: 3.252

10.  The effects of chronic versus acute desipramine on nicotine withdrawal and nicotine self-administration in the rat.

Authors:  Neil E Paterson; Svetlana Semenova; Athina Markou
Journal:  Psychopharmacology (Berl)       Date:  2008-04-29       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.